AU2014230014B2 - Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) - Google Patents

Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) Download PDF

Info

Publication number
AU2014230014B2
AU2014230014B2 AU2014230014A AU2014230014A AU2014230014B2 AU 2014230014 B2 AU2014230014 B2 AU 2014230014B2 AU 2014230014 A AU2014230014 A AU 2014230014A AU 2014230014 A AU2014230014 A AU 2014230014A AU 2014230014 B2 AU2014230014 B2 AU 2014230014B2
Authority
AU
Australia
Prior art keywords
cells
stem cells
stromal
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014230014A
Other languages
English (en)
Other versions
AU2014230014A1 (en
Inventor
Wilfried Dalemans
Olga De La Rosa
Eleuterio Lombardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of AU2014230014A1 publication Critical patent/AU2014230014A1/en
Application granted granted Critical
Publication of AU2014230014B2 publication Critical patent/AU2014230014B2/en
Priority to AU2020200807A priority Critical patent/AU2020200807B2/en
Assigned to TIGENIX, S.A.U. reassignment TIGENIX, S.A.U. Request for Assignment Assignors: TIGENIX NV, TIGENIX, S.A.U.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
AU2014230014A 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) Active AU2014230014B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200807A AU2020200807B2 (en) 2013-03-15 2020-02-05 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382091.0 2013-03-15
EP13382091 2013-03-15
PCT/EP2014/055282 WO2014140362A2 (en) 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200807A Division AU2020200807B2 (en) 2013-03-15 2020-02-05 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Publications (2)

Publication Number Publication Date
AU2014230014A1 AU2014230014A1 (en) 2015-10-29
AU2014230014B2 true AU2014230014B2 (en) 2019-11-14

Family

ID=48044710

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014230014A Active AU2014230014B2 (en) 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC)
AU2020200807A Active AU2020200807B2 (en) 2013-03-15 2020-02-05 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200807A Active AU2020200807B2 (en) 2013-03-15 2020-02-05 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Country Status (13)

Country Link
US (2) US10660920B2 (enExample)
EP (2) EP2972368B1 (enExample)
JP (2) JP6567430B2 (enExample)
AU (2) AU2014230014B2 (enExample)
CA (2) CA3188652A1 (enExample)
DK (1) DK2972368T3 (enExample)
ES (1) ES2748825T3 (enExample)
HU (1) HUE046531T2 (enExample)
IL (1) IL241586B (enExample)
PL (1) PL2972368T3 (enExample)
PT (1) PT2972368T (enExample)
SG (1) SG11201507521UA (enExample)
WO (1) WO2014140362A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
JP6811724B2 (ja) * 2015-04-24 2021-01-13 ティジェニクス エス．エー．ユー． 細胞療法に対する臨床応答を決定するためのバイオマーカー
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
TW201831681A (zh) * 2016-11-11 2018-09-01 美商生命科學公司 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
JP7628499B2 (ja) * 2019-02-27 2025-02-10 武田薬品工業株式会社 同種異系療法のための改良された幹細胞集団
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226828B1 (en) * 1999-10-20 2009-12-09 Chugai Seiyaku Kabushiki Kaisha Use of g-csf for inhibiting gvhd
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1871419A4 (en) * 2005-04-22 2009-01-14 Univ Maryland METHOD FOR THE TREATMENT OF TRANSPLANT-AGAINST RECIPIENT DISEASE
WO2012154344A1 (en) * 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENG JY et al, "Mesenchymal stem cell as salvage treatment for refractory chronic GVHD", Bone Marrow Transplantation, 2010, 45: 1732-1740 *

Also Published As

Publication number Publication date
PT2972368T (pt) 2019-10-18
HK1219775A1 (en) 2017-04-13
CA3188652A1 (en) 2014-09-18
JP6883070B2 (ja) 2021-06-09
US11478511B2 (en) 2022-10-25
WO2014140362A3 (en) 2015-04-16
EP2972368A2 (en) 2016-01-20
SG11201507521UA (en) 2015-10-29
US20160067285A1 (en) 2016-03-10
CA2906299A1 (en) 2014-09-18
JP2016516985A (ja) 2016-06-09
HUE046531T2 (hu) 2020-03-30
PL2972368T3 (pl) 2020-03-31
EP3581932A1 (en) 2019-12-18
WO2014140362A2 (en) 2014-09-18
AU2020200807B2 (en) 2021-10-28
AU2014230014A1 (en) 2015-10-29
JP2019215359A (ja) 2019-12-19
AU2020200807A1 (en) 2020-02-20
US10660920B2 (en) 2020-05-26
ES2748825T3 (es) 2020-03-18
IL241586B (en) 2019-02-28
DK2972368T3 (da) 2019-10-07
EP2972368B1 (en) 2019-07-24
JP6567430B2 (ja) 2019-08-28
US20200261511A1 (en) 2020-08-20
CA2906299C (en) 2023-04-04

Similar Documents

Publication Publication Date Title
US11478511B2 (en) Lymphocyte biomarkers for determining the clinical response to cell therapy
US20170121685A1 (en) Mesenchymal stem cell-derived exosomes and their uses
US10273449B2 (en) Induction medium and methods for stem cell culture and therapy
US20120027860A1 (en) Encapsulated adipose-derived stem cells, methods for preparation and theraputic use
EP2491115B1 (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20140154227A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
US20120020930A1 (en) Methods for the preparation of adipose derived stem cells and utilizing said cells in the treatment of diseases
US10746729B2 (en) Biomarkers for determining the clinical response to cell therapy
EP3307070B1 (en) Growth and survival compositions for cells capable of producing antibodies and methods related thereto
HK40019421A (en) Lymphocyte biomarkers for determining the clinical response to cell therapy
HK1219775B (en) Lymphocyte biomarkers for determining the clinical response to cell therapy
Devriendt et al. Abubakar Garba, Lowiese MB Desmarets, Delphine D. Acar, Inge DM Roukaerts
KR20190032197A (ko) 면역원성 감소 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TIGENIX, S.A.U.

Free format text: FORMER OWNER(S): TIGENIX, S.A.U.; TIGENIX NV